A randomized, single-site, parallel-group, prospective study of patients who are candidates for SLT, to study the effect of IOP change with Rocklatan vs artificial tears.

开始日期2025-02-14

申办/合作机构

Colorado Ophthalmology Associates, P C

NCT06441643

/ Recruiting临床2期

A Phase II, Prospective, Two-Stage, Double-Masked, Randomized, Multi-Center, Controlled, Dose-Response Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-17043 and PG043 (AR-17043/Latanoprost) Ophthalmic Solutions in Subjects With Elevated Intraocular Pressure

The purpose of this two-stage clinical trial is to assess the safety and hypotensive efficacy of AR-17043 and PG043 ophthalmic solutions in subjects with open-angle glaucoma (OAG) or ocular hypertension (OHT).

开始日期2024-09-04

申办/合作机构

Alcon Research Ltd.

NCT05283395

/ Completed临床4期

A Multicenter, Open-Label Rocklatan® (Netarsudil/Latanoprost Ophthalmic Solution) 0.02%/0.005% Evaluation of IOP Lowering Efficacy and Safety as Replacement of Current Medical Therapy Regimen for the Reduction of Elevated Intraocular Pressure in Patients With Glaucoma or Ocular Hypertension

The objective of this study is to evaluate the IOP-lowering effect when subjects are switched from various latanoprost-based regimens to Rocklatan. Subjects will stop their IOP-lowering medical therapy regimen and dose with Rocklatan for the duration of the study (12 weeks).

开始日期2022-03-28

申办/合作机构

Aerie Pharmaceuticals, Inc.

100 项与拉坦前列素/奈他地尔相关的临床结果

登录后查看更多信息

100 项与拉坦前列素/奈他地尔相关的转化医学

登录后查看更多信息

100 项与拉坦前列素/奈他地尔相关的专利（医药）

登录后查看更多信息

项与拉坦前列素/奈他地尔相关的文献（医药）

2024-01-01·Graefe's Archive for Clinical and Experimental Ophthalmology

MERCURY-3: a randomized comparison of netarsudil/latanoprost and bimatoprost/timolol in open-angle glaucoma and ocular hypertension

Article

作者: Lim, Kin Sheng ; Schweitzer, Cédric ; Fichtl, Marek ; Oddone, Francesco ; Belda, Jose I ; Laganovska, Guna ; Stalmans, Ingeborg ; Hommer, Anton ; Holló, Gábor ; Voykov, Bogomil ; Zarnowski, Tomasz

Abstract:

Purpose :

To compare the efficacy and safety of the fixed-dose combination (FDC) of netarsudil 0.02%/latanoprost 0.005% ophthalmic solution (NET/LAT; Roclanda®) with bimatoprost 0.03%/timolol maleate 0.5% (BIM/TIM; Ganfort®) ophthalmic solution in the treatment of open-angle glaucoma (OAG) and ocular hypertension (OHT).

Methods:

MERCURY-3 was a 6-month prospective, double–masked, randomized, multicenter, active-controlled, parallel-group, non-inferiority study. Patients (≥ 18 years) with a diagnosis of OAG or OHT in both eyes that was insufficiently controlled with topical medication (IOP ≥ 17 mmHg in ≥ 1 eye and < 28 mmHg in both eyes) were included. Following washout, patients were randomized to once-daily NET/LAT or BIM/TIM for up to 6 months; efficacy was assessed at Week 2, Week 4, and Month 3; safety was evaluated for 6 months. Comparison of NET/LAT relative to BIM/TIM for mean IOP at 08:00, 10:00, and 16:00 h was assessed at Week 2, Week 6, and Month 3. Non-inferiority of NET/LAT to BIM/TIM was defined as a difference of ≤ 1.5 mmHg at all nine time points through Month 3 and ≤ 1.0 mmHg at five or more of nine time points through Month 3.

Results:

Overall, 430 patients were randomized (NET/LAT, n = 218; BIM/TIM, n = 212), and all received at least one dose of study medication. Efficacy analyses were performed at Month 3 on 388 patients (NET/LAT, n = 184; BIM/TIM, n = 204). NET/LAT demonstrated non-inferiority to BIM/TIM, with a between-treatment difference in IOP of ≤ 1.5 mmHg achieved at all time points and ≤ 1.0 mmHg at the majority of time points (six of nine) through Month 3. Mean diurnal IOP during the study ranged from 15.4 to 15.6 mmHg and 15.2 to 15.6 mmHg in the NET/LAT and BIM/TIM groups respectively, with no between-group statistically significant difference. No significant differences were observed in key secondary endpoints. No serious, treatment-related adverse events (AEs) were observed, and AEs were typically mild/moderate in severity. The most common treatment-related AEs were conjunctival hyperemia (NET/LAT, 30.7%; BIM/TIM, 9.0%) and cornea verticillata (NET/LAT, 11.0%; BIM/TIM, 0%).

Conclusions:

Once-daily NET/LAT was non-inferior to BIM/TIM in IOP reduction in OAG and OHT, with AEs consistent with previous findings. NET/LAT offers a compelling alternative FDC treatment option for OAG and OHT.

2021-11-01·Veterinary ophthalmology

Safety and efficacy of topically administered netarsudil‐latanoprost fixed dose combination (FDC; Rocklatan™) in normal and glaucomatous dogs withADAMTS10‐open‐angle glaucoma (ADAMTS10‐OAG)

Article

作者: Komáromy, András M. ; Harman, Christine D. ; Anderson, Amanda L. ; Steibel, Juan P. ; Leary, Kelly A.

Abstract:

Objective:

The aim of the study was to evaluate safety and efficacy of topically administered 0.02% netarsudil‐0.005% latanoprost fixed‐dose combination (FDC) (Rocklatan™; Aerie Pharmaceutical) in normal and glaucomatous dogs withADAMTS10‐open‐angle glaucoma (ADAMTS10‐OAG).

Animals studied:

Five normal and five glaucomatous beagle dogs withADAMTS10‐OAG were the study animals.

Procedures:

In each dog, left (OS) or right eye (OD) was randomly selected for netarsudil‐latanoprost FDC treatment. Contralateral eyes served as latanoprost‐treated controls. The study was divided into four consecutive study periods: following a 4‐day baseline period, two sequential 8‐day study periods followed with once daily (q24h) and twice daily (q12h) treatments and ending with a washout period. Efficacy was measured by diurnal intraocular pressure (IOP) and pupil diameter. Safety was assessed by routine ophthalmic examination, gonioscopy, and pachymetry. Differences in least square means of quantitative outcome measures were compared between FDC and latanoprost treatments by using the linear Gaussian model.

Results:

Baseline IOPs were 13.6 ± 0.7 mmHg (mean ± SEM) in normal and 28.3 ± 1.4 mmHg in OAG‐affected dogs. There was a significant decrease in mean diurnal IOP following FDC administration in both normal (q24h: −2.1 mmHg; q12h: −4.1 mmHg) and glaucomatous dogs (q24h: −14.2 mmHg; q12h: −17.7 mmHg;p < .0001). There was no significant difference in the treatment effect when comparing FDC to latanoprost. Both FDC and latanoprost administration resulted in similarly significant pupil constriction (p < .0001). The FDC administration was well‐tolerated but resulted in conjunctival hyperemia.

Conclusions:

Once or twice daily administration of netarsudil‐latanoprost FDC (Rocklatan™) and latanoprost was equally effective in lowering IOP in normal and OAG‐affected dogs. There was no netarsudil‐related added treatment effect.

2020-04-29·Current medicinal chemistry2区 · 医学

Rho-kinase (ROCK) Inhibitors - A Neuroprotective Therapeutic Paradigm with a Focus on Ocular Utility

2区 · 医学

Review

作者: Piplani, Poonam ; Abbhi, Vasudha

Background::

Glaucoma is a progressive optic neuropathy causing visual impairment and Retinal Ganglionic Cells (RGCs) death gradually posing a need for neuroprotective strategies to minimize the loss of RGCs and visual field. It is recognized as a multifactorial disease, Intraocular Pressure (IOP) being the foremost risk factor. ROCK inhibitors have been probed for various possible indications, such as myocardial ischemia, hypertension, kidney diseases. Their role in neuroprotection and neuronal regeneration has been suggested to be of value in the treatment of neurological diseases, like spinal-cord injury, Alzheimer’s disease and multiple sclerosis but recently Rho-associated Kinase inhibitors have been recognized as potential antiglaucoma agents.

Evidence Synthesis::

Rho-Kinase is a serine/threonine kinase with a kinase domain which is constitutively active and is involved in the regulation of smooth muscle contraction and stress fibre formation. Two isoforms of Rho-Kinase, ROCK-I (ROCK β) and ROCK-II (ROCK α) have been identified. ROCK II plays a pathophysiological role in glaucoma and hence the inhibitors of ROCK may be beneficial to ameliorate the vision loss. These inhibitors decrease the intraocular pressure in the glaucomatous eye by increasing the aqueous humour outflow through the trabecular meshwork pathway. They also act as anti-scarring agents and hence prevent post-operative scarring after the glaucoma filtration surgery. Their major role involves axon regeneration by increasing the optic nerve blood flow which may be useful in treating the damaged optic neurons. These drugs act directly on the neurons in the central visual pathway, interrupting the RGC apoptosis and therefore serve as a novel pharmacological approach for glaucoma neuroprotection.

Conclusion::

Based on the results of high-throughput screening, several Rho kinase inhibitors have been designed and developed comprising of diverse scaffolds exhibiting Rho kinase inhibitory activity from micromolar to subnanomolar ranges. This diversity in the scaffolds with inhibitory potential against the kinase and their SAR development will be intricated in the present review. Ripasudil is the only Rho kinase inhibitor marketed to date for the treatment of glaucoma. Another ROCK inhibitor AR-13324 has recently passed the clinical trials whereas AMA0076, K115, PG324, Y39983 and RKI-983 are still under trials. In view of this, a detailed and updated account of ROCK II inhibitors as the next generation therapeutic agents for glaucoma will be discussed in this review.

项与拉坦前列素/奈他地尔相关的新闻（医药）

2024-01-10

·Pharmaceutical Technology

Alcon’s dry eye drug achieves primary endpoints in Phase III trials

AR-15512 is a transient receptor potential melastatin 8 (TRPM8) agonist, which was added to Alcon’s portfolio following the acquisition of Aerie Pharmaceuticals in November 2022. Image Credit: Rabizo Anatolii / Shutterstock. Switzerland-based Alcon’s dry eye disease drug AR-15512 achieved primary endpoints in two Phase III trials, COMET-2 and COMET-3. In light of the positive data, the company plans to file for a new drug application (NDA) for AR-15512 with the US Food and Drug Administration (FDA) in mid-2024, as per a 9 January press release. The vehicle-controlled Phase III COMET-2 (NCT05285644) and COMET-3 (NCT05360966) trials enrolled more than 930 patients, aged 30 years and older, with dry eye disease. The studies met their primary endpoints with a significant proportion of the patients in the treatment arm demonstrating at least a 10mm increase in unanaesthetised Schirmer’s score at day 14. An increase of 10mm or more in Schirmer’s score signifies normal tear production. The participants in the AR-15512 treatment arm also showed rapid onset and sustained tear production compared to the vehicle. The changes in tear production were observed on the first day and persisted for the whole 90-day study duration. Alcon noted that AR-15512 was well tolerated, with no serious ocular adverse events being reported during the trials. AR-15512 is a transient receptor potential melastatin 8 (TRPM8) agonist. TRPM8 is a cold-sensing receptor located in the cornea and eyelid and can potentially relieve symptoms of dry eye disease. It was added to Alcon’s portfolio following the $930m acquisition of Aerie Pharmaceuticals in November 2022. The acquisition also included marketed ophthalmic drugs such as Rocklatan, a netarsudil and latanoprost ophthalmic solution; and Rhopressa, a netarsudil ophthalmic solution. Both of these drugs are indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. The dry eye disease market is forecasted to generate $11.1bn in sales across the seven major markets in 2028, as per GlobalData analysis . GlobalData is the parent company of Pharmaceutical Technology . Another late-stage drug being developed as a treatment for dry eye disease is Aldeyra Therapeutics’ reproxalap. The drug had a mixed bag of results as it demonstrated significant improvement in the Schirmer test in both Phase III TRANQUILITY (NCT04674358)and TRANQUILITY-2 (NCT05062330) trials but failed to meet its primary endpoint of reduction in conjunctival redness in the Phase III TRANQUILITY trial. In November 2023, the FDA rejected the reproxalap’s NDA and requested additional data to show the drug’s efficacy.

临床结果临床3期并购申请上市临床成功

2024-01-09

·BioSpace

Alcon Announces Positive Topline Results From Phase 3 COMET Trials of AR-15512, a Novel Topical Drug Candidate for Dry Eye

AR-15512, a topical transient receptor potential melastatin 8 (TRPM8) agonist, is a first-in-class product candidate for the treatment of the signs and symptoms of dry eye disease In both pivotal efficacy and safety studies (COMET-2 and COMET-3), the primary endpoint was achieved (p <0.0001) Dry eye affects an estimated 38 million people in the U.S. and less than 10% of diagnosed patients are treated with a prescription product1 GENEVA--(BUSINESS WIRE)-- Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced positive topline results from the two pivotal Phase 3 clinical trials (COMET-2 and COMET-3) evaluating the efficacy and safety of AR-15512, a candidate treatment for the signs and symptoms of dry eye disease (DED). In both COMET-2 and COMET-3, which enrolled more than 930 dry eye subjects in total (randomized 1:1 to AR-15512 or vehicle control), the primary endpoint of the proportion of subjects with at least a 10-mm increase in unanesthetized Schirmer’s score (a measure of tear production) achieved statistical significance at Day 14 [p<0.0001]. These data are consistent with the proposed mechanism of action of AR-15512. “We are excited by AR-15512 as it has the potential to address the limitations of current dry eye prescription options and provide Eye Care Professionals (ECPs) and dry eye sufferers with a new and effective approach to the management of dry eye, a chronic and undertreated disease,” said David Endicott, CEO of Alcon. “AR-15512 is the first product candidate in our emerging ophthalmic pharmaceutical portfolio, representing our legacy of commitment to innovation in eye care.” AR-15512 represents an opportunity to bring relief to dry eye sufferers. While DED is one of the most common ocular disorders, affecting an estimated 38 million people in the U.S., only about 18 million are diagnosed and less than 10% of those diagnosed are treated with a prescription product. This represents the significant need for an effective chronic treatment that can provide rapid natural tear production.1 In these studies, additional data derived from secondary endpoints demonstrated the rapid onset and sustained tear production associated with AR-15512 compared to vehicle, as early as Day 1 and persistent to Day 90. Overall, AR-15512 was well tolerated and no serious ocular adverse events were reported. “A key gap in dry eye medications is rapid speed of onset,” said Edward Holland, MD, Professor of Ophthalmology at the University of Cincinnati, a key advisor on COMET-2 and -3 and Senior Scientific Advisor at Alcon. “AR-15512 demonstrated this important achievement in both pivotal efficacy and safety studies and it represents a first-in-class candidate for chronic dry eye.” AR-15512 is an investigational drug product that has not been submitted to the U.S. Food and Drug Administration (FDA) for approval and is not currently commercially available. Alcon anticipates filing the NDA for AR-15512 with FDA in mid-2024. Alcon's ophthalmic pharmaceutical portfolio currently includes Rocklatan®, Rhopressa®, Simbrinza®, Eysuvis®, and Inveltys®. About Dry Eye Dry eye disease is one of the most common ocular surface disorders, affecting an estimated 38 million adults in the United States and an estimated 719 million more adults globally.1 While once considered a disease of aging populations, modern advancements, such as prolonged digital screen time, have contributed to a significant rise in DED across age and gender.2 Many existing prescription options for dry eye disease are generally regarded by many eye care professionals and patients as inadequate due to low treatment efficacy, slow onset of action and/or poor tolerability.3 About Alcon Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years, we offer the broadest portfolio of products to enhance sight and improve people’s lives. Our Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. Our more than 25,000 associates are enhancing the quality of life through innovative products, partnerships with Eye Care Professionals and programs that advance access to quality eye care. Learn more at . Cautionary Note Regarding Forward-looking Statements This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “anticipate,” “intend,” “commitment,” “look forward,” “maintain,” “plan,” “goal,” “seek,” “target,” “assume,” “believe,” “project,” “estimate,” “expect,” “strategy,” “future,” “likely,” “may,” “should,” “will” and similar references to future periods. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties and risks that are difficult to predict. Some of these factors are discussed in our filings with the United States Securities and Exchange Commission, including our Form 20-F. Should one or more of these uncertainties or risks materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated. Therefore, you should not rely on any of these forward-looking statements. Forward-looking statements in this press release speak only as of the date they are made, and we assume no obligation to update forward-looking statements as a result of new information, future events or otherwise. References Market Scope 2023 Dry Eye Product Market Review; does not include OTC artificial tears and other Rx anti-inflammatory and tear stimulants. The Relationship Between Dry Eye Disease and Digital Screen Use - PMC (nih.gov) Improved Dry Eye Drugs for 2022 and Beyond; Connect with us on Facebook LinkedIn

临床结果临床3期临床1期申请上市

2023-10-19

·BioSpace

Skye Bioscience to Host Virtual Investor Day on October 25, 2023: "CB1 Axis: Unlocking the Pharmaceutical Potential of the Endocannabinoid System"

Phase 1 clinical data to be released in conjunction with Investor Day San Diego, California--(News - October 19, 2023) - Skye Bioscience, Inc. (OTCQB: SKYED) ("Skye" or the "Company"), a pharmaceutical company developing drugs targeting the endocannabinoid system, initially through modulation of the CB1 receptor, to address diseases including glaucoma and metabolic conditions, announces that it will host a virtual Investor Day, called "CB1 Axis: Unlocking the Pharmaceutical Potential of the Endocannabinoid System", on Wednesday, October 25, 2023 at 8:00am ET. To register, click here. In conjunction with this event, Skye will also release its Phase 1 clinical data. The event will feature Brian Levy, O.D. (former CMO, Aerie and Bausch & Lomb), Glenwood Gum, Ph.D. (Pharmaron), and Sameh Mosaed, M.D., Ph.D. (UC Irvine), who will provide an overview of the current glaucoma commercial landscape, drug development pipeline, and perspective on the historical challenges to achieving CB1-targeting therapeutics for the treatment of glaucoma. Skye leadership will provide broad insight into SBI-100 Ophthalmic Emulsion, its CB1 agonist being developed to potentially treat glaucoma, including a nonclinical data overview, clinical data from the company's recently completed Phase 1 study, a Phase 2 clinical update, and an outline of the glaucoma market opportunity and Skye's positioning strategy. A live question and answer session will follow the formal presentations. About Brian Levy, O.D. Dr. Brian Levy, CEO of InflammX Therapeutics, leads the development of Xiflam for dry AMD and diabetic eye/kidney diseases, now in a Phase 2 trial with NIH's DRCR Retinal Network. Formerly CMO at Aerie Pharmaceuticals, he pioneered rho kinase inhibition treatments, including the approvals of Rhopressa® and Rocklatan®. As VP of R&D at Bausch & Lomb for 15 years, he oversaw approvals of Retisert, Zylet, and Besivance. A seasoned ophthalmologist with over 50 publications, Levy holds degrees from UC Berkeley and University of Waterloo. About Glenwood Gum, Ph.D. Dr. Gum has 40+ years' experience in ophthalmology research and development in an academic and industry setting. As the Sr. Director of Ophthalmology at Pharmaron, he's advanced ocular studies, especially using the glaucomatous beagle model. His collaboration with renowned pharmaceutical companies has led to breakthroughs in beta blockers, cannabinoids, and prostaglandins. About Sameh Mosaed, M.D., Ph.D. Dr. Sameh Mosaed, MD, is a Professor of Ophthalmology and Chief of Glaucoma at UC Irvine's Gavin Herbert Eye Institute. She directs the glaucoma fellowship training program and is renowned for her minimally invasive glaucoma surgery expertise. Dr. Mosaed is credited with over 50 published papers and numerous textbook chapters. About SBI-100 Ophthalmic Emulsion Skye's SBI-100 OE possesses a novel molecular structure and nanoemulsion formulation designed to enable effective topical delivery and better penetration of a CB1 agonist into ocular tissue. In preclinical studies involving three different species, the drug resulted in enhanced therapeutic efficacy and duration of response in lowering IOP, comparing favorably to the standard of care for treating glaucoma. About Skye Bioscience Skye is focused on unlocking the pharmaceutical potential of the endocannabinoid system to treat diseases with inflammatory, fibrotic, and metabolic processes. Backed by leading life science venture investors, Skye's strategy leverages biologic targets with substantial human proof of mechanism for the development of first-in-class therapeutics with significant clinical and commercial differentiation. Nimacimab, a negative allosteric modulating antibody, inhibits peripheral CB1 with unprecedented safety and tolerability. A Phase 2 cardio-metabolic related indication study is expected to start in Q1 2024. Skye is also evaluating potential development paths for nimacimab related to obesity and weight loss. SBI-100 Ophthalmic Emulsion is a CB1 agonist that is a potential treatment for glaucoma and is expected to start a Phase 2 clinical trial in Q4 2023. For more information, please visit: . CONTACT Investor Relations Email: ir@skyebioscience.com Phone: (858) 410-0266 FORWARD-LOOKING STATEMENTS This letter contains forward-looking statements, including statements regarding our product development, business strategy, the timing of clinical trials, and commercialization of cannabinoid-derived therapeutics. Such statements and other statements in this press release that are not descriptions of historical facts are forward-looking statements that are based on management's current expectations and assumptions and are subject to risks and uncertainties. If such risks or uncertainties materialize or such assumptions prove incorrect, our business, operating results, financial condition, and stock price could be materially negatively affected. In some cases, forward-looking statements can be identified by terminology including "anticipated," "plans," "goal," "focus," "aims," "intends," "believes," "can," "could," "challenge," "predictable," "will," "would," "may" or the negative of these terms or other comparable terminology. We operate in a rapidly changing environment, and new risks emerge from time to time. As a result, it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements the Company may make. Risks and uncertainties that may cause actual results to differ materially include, among others, our capital resources, uncertainty regarding the results of future testing and development efforts and other risks that are described in the Risk Factors section of Skye's most recent annual or quarterly report filed with the Securities and Exchange Commission. Except as expressly required by law, Skye disclaims any intent or obligation to update these forward-looking statements. To view the source version of this press release, please visit

临床1期临床2期

100 项与拉坦前列素/奈他地尔相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	S01E	-

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
开角型青光眼	美国	Alcon Laboratories, Inc.	2019-03-12
高眼压症	美国	Alcon Laboratories, Inc.	2019-03-12

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
青光眼	临床3期	美国	Aerie Pharmaceuticals, Inc.	2014-09-01
低眼压	临床3期	美国	Aerie Pharmaceuticals, Inc.	2014-07-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05283395 (CTgov)	临床4期	青光眼	136	Latanoprost+Rocklatan (Rocklatan (Latanoprost Mono))	艱簾繭壓鏇鹽範鏇築壓(願膚願糧窪膚餘遞鹽廠) = 襯顧糧壓壓窪壓憲構廠衊範艱鹽蓋醖遞齋餘餘 (餘範遞簾鏇醖選鹽膚簾, 17.46) 更多	-	2024-04-03
				Latanoprost+Rocklatan (Rocklatan (Latanoprost +1))	艱簾繭壓鏇鹽範鏇築壓(願膚願糧窪膚餘遞鹽廠) = 廠鑰糧糧窪繭繭構鹽醖衊範艱鹽蓋醖遞齋餘餘 (餘範遞簾鏇醖選鹽膚簾, 21.91) 更多
APAO2023	N/A	青光眼	-	Netarsudil-Latanoprost Fixed-Dose Combination (NLFC)	繭齋糧網蓋艱衊夢膚繭(夢鏇衊艱衊觸鹹鏇簾鑰) = 積蓋繭遞獵糧醖憲襯願構顧齋築壓衊願衊醖餘 (鑰壓築鬱選夢獵遞淵網 )	-	2023-02-23
NCT03284853 (Mercury 3, CTgov)	临床3期	开角型青光眼	436	Netarsudil/Latanoprost 0.02%/0.005% (Netarsudil/Latanoprost 0.02%/0.005%)	廠糧窪築鹹願餘窪觸範(鏇齋襯簾餘顧餘簾鬱衊) = 簾鬱壓遞築網繭範鹹願鏇淵醖鬱壓鑰範壓襯糧 (襯顧蓋網艱製餘鏇醖衊, 膚廠鹹衊製鏇願製顧簾 ~ 壓積簾憲衊憲範鬱遞鏇) 更多	-	2022-01-19
				GANFORT® (GANFORT®)	廠糧窪築鹹願餘窪觸範(鏇齋襯簾餘顧餘簾鬱衊) = 窪鏇構壓壓鏇襯顧築鏇鏇淵醖鬱壓鑰範壓襯糧 (襯顧蓋網艱製餘鏇醖衊, 製鏇構壓築遞齋築醖觸 ~ 廠鹽構鑰顧鏇鹹顧壓觸) 更多
APAO2021	N/A	青光眼	-	Netarsudil Latanoprost Fixed Combination (NLFC)	襯構膚襯鏇選築壓觸蓋(範鹽鹹簾顧鑰鹹壓廠鏇) = Pre-switch hyperemia: 0 (11) 0.5 -1 (9) + 2 (3) + 2 (1); Post-switch hyperemia: 0 (12) +0.5-1 (6) + 2 (4) + 3 (2) 憲膚窪範廠襯積觸築製 (鏇構餘選範齋糧簾鹽襯 )	-	2021-09-05
NCT03284853 (Mercury 3, BusinessWire) 人工标引	临床3期	高眼压症 \| 开角型青光眼	430	Latanoprost+Roclanda	築鹽選糧膚範艱積範衊(壓網醖製鑰製鬱廠簾網) = Roclanda demonstrated consistent IOP reduction throughout the day of approximately 9.5 millimeters of mercury (mmHg) for an average reduction from baseline IOPs of approximately 37 percent 構窪觸願壓膚糧膚製獵 (膚窪淵憲餘艱構觸鬱遞 )	非劣	2020-09-24
				Bimatoprost+Timolol
NCT03310580 (CTgov)	临床2期	开角型青光眼	42	AR-13324 Ophthalmic Solution 0.02% (AR-13324 Ophthalmic Solution 0.02%)	獵衊糧廠觸積窪鏇窪繭(艱齋網淵範鏇膚壓齋製) = 鏇鑰衊窪壓繭淵觸艱鏇範鏇願淵夢鏇鏇憲壓願 (積窪顧壓廠顧餘遞憲膚, 0.549) 更多	-	2019-11-15
				AR-13324 Ophthalmic Solution 0.04% (AR-13324 Ophthalmic Solution 0.04%)	獵衊糧廠觸積窪鏇窪繭(艱齋網淵範鏇膚壓齋製) = 糧構夢鬱網築齋鹽壓製範鏇願淵夢鏇鏇憲壓願 (積窪顧壓廠顧餘遞憲膚, 0.567) 更多
NCT02057575 (CTgov)	临床2期	开角型青光眼	298	PG324 Ophthalmic Solution 0.01% (PG324 Ophthalmic Solution 0.01%)	鹽願選願蓋網醖憲簾鑰(獵憲醖廠鑰鬱範遞淵齋) = 憲觸鹹獵醖壓範顧鏇鬱壓淵廠顧簾壓鹹網鏇餘 (憲獵糧顧遞夢選窪築構, 2.330) 更多	-	2019-06-04
				PG324 Ophthalmic Solution 0.02% (PG324 Ophthalmic Solution 0.02%)	鹽願選願蓋網醖憲簾鑰(獵憲醖廠鑰鬱範遞淵齋) = 糧選壓淵鬱齋觸餘鏇餘壓淵廠顧簾壓鹹網鏇餘 (憲獵糧顧遞夢選窪築構, 2.374) 更多
NCT02558400 (CTgov)	临床3期	开角型青光眼	718	Netarsudil (AR-13324) Ophthalmic Solution 0.02% (AR-13324 Ophthalmic Solution 0.02%)	鑰壓膚夢網醖築範積艱(選窪鬱廠衊夢餘糧壓願) = 構糧醖夢艱夢網壓鑰鬱淵構鬱鹹糧糧壓築齋積 (鑰遞廠膚壓願願糧鹽鬱, 3.335) 更多	-	2019-06-04
				Latanoprost Ophthalmic Solution 0.005% (Latanoprost Ophthalmic Solution 0.005%)	鑰壓膚夢網醖築範積艱(選窪鬱廠衊夢餘糧壓願) = 選鬱觸鬱襯製願鏇餘獵淵構鬱鹹糧糧壓築齋積 (鑰遞廠膚壓願願糧鹽鬱, 2.914) 更多
NCT02674854 (CTgov)	临床3期	开角型青光眼	750	Netarsudil (AR-13324) ophthalmic solution 0.02% (Netarsudil (AR-13324) Ophthalmic Solution 0.02%)	醖襯範蓋鏇衊醖蓋網憲(淵襯糧觸鏇網鑰窪憲製) = 網衊鏇襯蓋夢壓蓋構範糧顧餘觸淵膚廠築鏇廠 (壓艱艱繭壓壓廠鏇廠觸, 3.148) 更多	-	2019-05-01
				Latanoprost ophthalmic solution 0.005% (Latanoprost Ophthalmic Solution 0.005%)	醖襯範蓋鏇衊醖蓋網憲(淵襯糧觸鏇網鑰窪憲製) = 膚築廠簾顧範積蓋築簾糧顧餘觸淵膚廠築鏇廠 (壓艱艱繭壓壓廠鏇廠觸, 3.240) 更多
NCT02246764 (CTgov)	临床3期	青光眼 \| 低眼压	93	Placebo+AR-13324 Ophthalmic Solution 0.02% (AR-13324 Ophthalmic Solution 0.02% & Placebo)	夢鑰艱積範遞願襯網顧(鹽襯顧窪淵餘繭憲顧夢) = 襯憲艱餘壓繭廠範積製壓繭築廠衊壓遞觸廠簾 (鬱齋獵壓觸選鬱蓋鬱鏇, 137.28) 更多	-	2018-04-06
				AR-13324 Ophthalmic Solution 0.02% BID (AR-13324 Ophthalmic Solution 0.02% BID)	夢鑰艱積範遞願襯網顧(鹽襯顧窪淵餘繭憲顧夢) = 鏇憲積鏇獵餘遞範築鑰壓繭築廠衊壓遞觸廠簾 (鬱齋獵壓觸選鬱蓋鬱鏇, 105.69) 更多